BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 11428932)

  • 1. Peptide analogues of a subdominant epitope expressed in ebv-associated tumors: synthesis and immunological activity.
    Marastoni M; Bazzaro M; Micheletti F; Gavioli R; Tomatis R
    J Med Chem; 2001 Jul; 44(14):2370-3. PubMed ID: 11428932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxic T lymphocyte epitope analogues containing cis- or trans-4-aminocyclohexanecarboxylic acid residues.
    Marastoni M; Bazzaro M; Micheletti F; Gavioli R; Tomatis R
    Bioorg Med Chem; 2002 Sep; 10(9):3061-6. PubMed ID: 12110330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective amino acid substitutions of a subdominant Epstein-Barr virus LMP2-derived epitope increase HLA/peptide complex stability and immunogenicity: implications for immunotherapy of Epstein-Barr virus-associated malignancies.
    Micheletti F; Guerrini R; Formentin A; Canella A; Marastoni M; Bazzaro M; Tomatis R; Traniello S; Gavioli R
    Eur J Immunol; 1999 Aug; 29(8):2579-89. PubMed ID: 10458773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of dimeric peptides obtained from a subdominant Epstein-Barr virus LMP2-derived epitope.
    Marastoni M; Bazzaro M; Gavioli R; Micheletti F; Traniello S; Tomatis R
    Eur J Med Chem; 2000 Jun; 35(6):593-8. PubMed ID: 10906411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.
    Khanna R; Burrows SR; Nicholls J; Poulsen LM
    Eur J Immunol; 1998 Feb; 28(2):451-8. PubMed ID: 9521052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphonuclear neutrophils pulsed with synthetic peptides efficiently activate memory cytotoxic T lymphocytes.
    Reali E; Guerrini R; Moretti S; Spisani S; Lanza F; Tomatis R; Traniello S; Gavioli R
    J Leukoc Biol; 1996 Aug; 60(2):207-13. PubMed ID: 8773582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL.
    Chen JL; Dunbar PR; Gileadi U; Jäger E; Gnjatic S; Nagata Y; Stockert E; Panicali DL; Chen YT; Knuth A; Old LJ; Cerundolo V
    J Immunol; 2000 Jul; 165(2):948-55. PubMed ID: 10878370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
    Rivoltini L; Kawakami Y; Sakaguchi K; Southwood S; Sette A; Robbins PF; Marincola FM; Salgaller ML; Yannelli JR; Appella E
    J Immunol; 1995 Mar; 154(5):2257-65. PubMed ID: 7868898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of epitope-specific memory cytotoxic T lymphocyte responses by synthetic peptides.
    Reali E; Guerrini R; Giori B; Borghi M; Marastoni M; Tomatis R; Traniello S; Masucci MG; Gavioli R
    Clin Exp Immunol; 1996 Aug; 105(2):369-75. PubMed ID: 8706347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.
    Tan LC; Mowat AG; Fazou C; Rostron T; Roskell H; Dunbar PR; Tournay C; Romagné F; Peyrat MA; Houssaint E; Bonneville M; Rickinson AB; McMichael AJ; Callan MF
    Arthritis Res; 2000; 2(2):154-64. PubMed ID: 11062606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteasome inhibitors reconstitute the presentation of cytotoxic T-cell epitopes in Epstein-Barr virus-associated tumors.
    Gavioli R; Vertuani S; Masucci MG
    Int J Cancer; 2002 Oct; 101(6):532-8. PubMed ID: 12237893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Supra-agonist peptides enhance the reactivation of memory CTL responses.
    Micheletti F; Canella A; Vertuani S; Marastoni M; Tosi L; Volinia S; Traniello S; Gavioli R
    J Immunol; 2000 Oct; 165(8):4264-71. PubMed ID: 11035060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A HLA-A2 restricted human CTL line recognizes a novel tumor cell expressed p53 epitope.
    Würtzen PA; Claesson MH
    Int J Cancer; 2002 Jun; 99(4):568-72. PubMed ID: 11992547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.
    Eguchi J; Hatano M; Nishimura F; Zhu X; Dusak JE; Sato H; Pollack IF; Storkus WJ; Okada H
    Cancer Res; 2006 Jun; 66(11):5883-91. PubMed ID: 16740728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.
    Lee SP; Tierney RJ; Thomas WA; Brooks JM; Rickinson AB
    J Immunol; 1997 Apr; 158(7):3325-34. PubMed ID: 9120290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus.
    Solache A; Morgan CL; Dodi AI; Morte C; Scott I; Baboonian C; Zal B; Goldman J; Grundy JE; Madrigal JA
    J Immunol; 1999 Nov; 163(10):5512-8. PubMed ID: 10553078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
    Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J
    Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epitope-enhanced conserved HIV-1 peptide protects HLA-A2-transgenic mice against virus expressing HIV-1 antigen.
    Okazaki T; Pendleton CD; Lemonnier F; Berzofsky JA
    J Immunol; 2003 Sep; 171(5):2548-55. PubMed ID: 12928405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melanoma peptide MART-1(27-35) analogues with enhanced binding capacity to the human class I histocompatibility molecule HLA-A2 by introduction of a beta-amino acid residue: implications for recognition by tumor-infiltrating lymphocytes.
    Guichard G; Zerbib A; Le Gal FA; Hoebeke J; Connan F; Choppin J; Briand JP; Guillet JG
    J Med Chem; 2000 Oct; 43(20):3803-8. PubMed ID: 11020297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4.
    Levitsky V; Zhang QJ; Levitskaya J; Masucci MG
    J Exp Med; 1996 Mar; 183(3):915-26. PubMed ID: 8642295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.